ConductScience.org, home

Comparison · NCT03138733-2379bb3a

Ceftobiprole vs Daptomycin: Number of Patients With Microbiological Eradication at the PTE Visit

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Ceftobiprole vs Daptomycin: Number of Patients With Microbiological Eradication at the PTE Visit. Trial comparisons, record NCT03138733-2379bb3a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03138733-2379bb3a

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.820.7590.868wilson
Risk in group 20.7730.7090.826wilson
Risk difference, group 1 minus group 20.0474-0.03330.127newcombe hybrid score
Risk ratio, group 1 over group 21.060.961.17log
Odds ratio, group 1 over group 21.340.8152.21log
Number needed to treat, for one more participant with the outcome on Ceftobiprole than on Daptomycin21.1from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1CeftobiproleCeftobiprole 500 mg (as 667 mg ceftobiprole medocaril)~Ceftobiprole: Ceftobiprole 500 mg as a 2 h infusion155189OG000
Group 2DaptomycinDaptomycin 6 mg/kg, with or without aztreonam~Daptomycin: Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards) as a 0.5 h infusion, with or without aztreonam153198OG001

Outcome

Type
SECONDARY
Title
Number of Patients With Microbiological Eradication at the PTE Visit
Description
Comparison of microbiological eradication rates in the mITT population. Microbiological eradication rate was defined as a negative blood culture for S. aureus during study treatment and another negative blood culture during the follow up period up to PTE.
Time frame
At PTE visit on Day 70 (± 5 days) post-randomization
Population
The mITT population comprised the subset of patients in the ITT population who received any dose of study medication, and had a blood culture positive for S. aureus at baseline

Source ClinicalTrials.gov

Trial

Title
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
NCT number
NCT03138733
Phases
PHASE3
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Ceftobiprole medocaril, Daptomycin
Lead sponsor
Basilea Pharmaceutica
Results first posted
2023-05-06

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03138733-2379bb3a